As GLP-1 is rapidly degraded by dipeptidyl peptidase-4 (DPP-4), DPP-4 inhibitors that are widely used to treat type 2 diabetes could be a potential treatment for DKD in part because of their pleiotropic actions. This evidence concerns the gene DPP4 and diabetic kidney disease.